Seattle Genetics Inc. plans to proceed with a late-stage study of a possible additional use for its lymphatic cancer treatment Adcetris after releasing results from a small, early-stage test.

The Bothell, Wash., company said Sunday 23 of 26 patients with an aggressive form of non-Hodgkin lymphoma who received Adcetris combined with chemotherapy achieved complete remission, which means they had no trace of the cancer after the treatment was completed.

CEO Clay B. Siegall said in a statement the data offers a "strong rationale" for late-stage testing that will compare Adcetris combined with chemotherapy to the standard chemotherapy treatment for the disease. The company plans to start the trial by early next year.

Seattle Genetics announced the results at the American Society of Hematology's annual meeting in Atlanta.

Adcetris is Seattle Genetics' only marketed product. It is already approved to treat two types of lymphoma. The company also is seeking approval to market the drug as a treatment for mycosis fungoides, a type of non-Hodgkin lymphoma that starts in the skin.

Last month, the Food and Drug Administration gave the treatment orphan drug status for that indication. That means that if Adcetris is approved as a treatment for that disease, the FDA won't approve similar products for seven years.

Orphan drug status is given to treatments for disease that affect fewer than 200,000 Americans.

Shares of Seattle Genetics fell 14 cents to $25.40 in Monday morning trading, while the Nasdaq exchange rose less than 1 percent. The company's shares are still up about 52 percent since closing 2011 at $16.72.

Link:
Seattle Genetics to test possible new Adcetris use

Recommendation and review posted by Bethany Smith

AMSTERDAM, December 11, 2012 /PRNewswire/ --

uniQure B.V., a leader in the field of human gene therapy, today announced the start of its Phase I clinical trial in acute intermittent porphyria (AIP) with the treatment of the first patient. The study is conducted under the aegis of the AIPGENE consortium, a pan-European collaboration funded in part by the European Commission's Seventh Framework Program with the aim to develop a gene therapy for the treatment of AIP, a rare and devastating disease caused by mutations in the porphobilinogen deaminase gene (PBGD). AIP can be life-threatening and the long-term effects include irreversible nerve damage, liver cancer and kidney failure. uniQure was granted orphan drug designation for the treatment of AIP in 2009 from the European Medicines Agency.

"The start of the AIP Phase I study marks the first of four programs that will enter clinical trials over the next 12 months," says Jrn Aldag, CEO of uniQure. "After AIP we expect clinical trials to be initiated in Parkinson's disease, hemophilia B, and Sanfilippo B. After many years of building and developing our capabilities and competencies, and the approval in November of Glybera for LPLD as the first gene therapy in the Western world, we are highly motivated to expedite the clinical development of our other advanced gene therapies."

About the AIP Phase I study

The Phase I will enroll eight patients with severe AIP at two centers: the Clinical University of Navarra, Pamplona, Spain, and the 12 de Octubre University Hospital,, Madrid, Spain. The study's primary objective is the assessment of safety and determination of the maximum tolerated dose. Secondary objectives include tolerability of treatment, pharmacokinetics, changes in the levels of surrogate markers of activity including porphobilinogen (PBG) and delta-aminolevulinic acid (ALA), and assessment of symptom control, neuro-psychological changes and quality of life. All patients will be followed for one year, and the interim results of the Phase I are expected in Q3 2013.

About acute intermittent porphyria

Acute Intermittent porphyria (AIP) is a rare genetic disease which is caused by mutations in the porphobilinogen deaminase (PBGD) gene; one of the enzymes of the heme biosynthesis pathway. Mutations in this gene cause insufficient activity of the protein resulting in partially disruption of heme synthesis. This in turn leads to accumulation of toxic intermediates (ALA and PBG) giving rise to a wide variety of problems including acute, severe abdominal pains, psychiatric and neurological disorders, and muscular weakness. Acute porphyric attacks can be life-threatening and the long-term consequences include irreversible nerve damage, liver cancer and kidney failure. Currently, the only curative therapy is liver transplantation and thus, new curative options are urgently needed. Severe AIP patients are suffering poor quality of life with palliative treatments for the different symptoms including glucose or heme infusions for metabolic replacement and inhibition of toxic metabolic production.

About AIPGENE

AIPGENE is a European Commission Framework Programme 7-funded consortium (Grant Agreement number 261506) which was put together with the aim to develop the orphan gene therapy drug AAV5-AAT-PBGD (AMT-021) for the treatment of Acute Intermittent porphyria (AIP). The consortium's objective is to contribute to alleviating the negative impact of this disease on the quality of life of the patients and their families. Overall coordinator of the project is the Centre for Applied Medical Research (CIMA) at the University of Navarra, Pamplona, Spain. Apart from uniQure, other members of the consortium are the Clinical University of Navarra, Pamplona, Spain; Karolinska University Hospital, Stockholm, Sweden; German Cancer Research Center (NCT-DKFZ), Heidelberg, Germany; DIGNA Biotech, Pamplona, Spain; Servicio Madrileno de Salud, Madrid, Spain.

About uniQure

Read this article:
uniQure Initiates Phase I in Acute Intermittent Porphyria

Recommendation and review posted by Bethany Smith

STAMFORD, Conn.--(BUSINESS WIRE)--

Alliance for Cancer Gene Therapy (ACGT), the nations only non-profit organization dedicated exclusively to funding cell and gene therapy research for cancer, is excited to play a major role in the recent leukemia study pioneered by scientists at the Perelman School of Medicine at the University of Pennsylvania. ACGT was the initial funding arm for the study using immune-mediated gene therapy for leukemia and lymphoma. This study illustrates the successful and sustained demonstration of how gene therapy uses the bodys own T-cells and turns them into weapons aimed directly at cancer.

Initial ACGT grants were awarded in 2004 to Dr. Carl June of the Abramson Family Cancer Research Institute at the University of Pennsylvania, and to Dr. Michel Sadelain, of Memorial Sloan-Kettering Cancer Center, Gene Therapy & Gene Expression Laboratory in New York City. Preliminary results were issued by Dr. Carl June and the University of Pennsylvania in August 2011, with additional results released this week and presented by Dr. Carl June at the American Society of Hematologys Annual Meeting and Exposition being held in Atlanta, Georgia.

The clinical trial participants, all of whom had advanced cancers, included ten adult patients with chronic lymphocytic leukemia, were treated at the Hospital of the University of Pennsylvania (HUP) and two children with acute lymphoblastic leukemia were treated at the Childrens Hospital of Philadelphia (CHOP). Two of the first three patients treated with the protocol at HUP whose cases were detailed in The New England Journal of Medicine and Science Translational Medicine in August 2011 remain healthy and in full remission more than two years after their treatment, with the engineered cells still circulating in their bodies. Currently, nine out of 12 of the participants show their disease in remission.

The discovery of successful cancer gene therapy treatments are what my husband and I hoped for when we founded ACGT a decade ago, noted Barbara Netter, president and co-founder of the Alliance for Cancer Gene Therapy. We knew it would be an uphill battle. ACGT was the only organization willing to take the risk when others were not. With federal funds decreasing, and the realization that pharmaceutical companies will not participate in the research phase until marketable and mass-produced treatments are created, we seized the chance to make a difference. My late husband Edward Netter (1932-2011), was a true visionary in the field of medical research. He would be so thrilled by the progress ACGT has made possible.

ACGT is currently funding 17 clinical trials in cancer cell and gene therapy targeting numerous types of cancers. Since its inception, ACGT has awarded more than $23 million in grants to 39 investigators to treat 11 different types of cancer. In 2012, ACGT also awarded a $500,000 grant to a clinical translational study on pancreatic cancer and has great expectations for its outcome. In ACGTs 2011 grant cycle, 87 scientists from throughout the U.S. responded with grant applications for ACGTs Young Investigator Grants, making 2011 one of the most sought-after funding year in ACGT history. The ACGT funded clinical studies are already showing promise, especially in the treatment of leukemia, lung, melanoma and prostate cancers.

It is so exciting that the pathfinder role ACGT played by provided the seed money for the University of Pennsylvania trial has led to these stunning successes for leukemia treatment, said Dr. Savio Woo, chairman of ACGTs Scientific Advisory Council, and founding Chair of the Department of Gene and Cell Medicine at Mt. Sinai School of Medicine in New York City.

Woo noted that 100 percent of all funds donated to ACGT go directly toward funding innovative cancer gene therapy research grants. ACGTs Scientific Advisory Council, which comprises some of the best scientific minds and thought leaders with major U.S. medical institutions, oversee all phases of the ACGT grant process. Through this rigorous review, ACGT is able to identify and fund studies with the most potential for positive and innovative outcomes for treating cancer using cell and gene therapy.

The University of Pennsylvanias initial study was funded primarily by ACGT. The most recent clinical trial was also supported by ACGT, the Leukemia & Lymphoma Society (Dr. June is the leader of one of the LLSs grants), and the National Institutes of Health. In addition, Novartis announced this summer that it would fund additional research at the University of Pennsylvania to further study the immunotherapies and has acquired exclusive rights to market the treatment.

Alliance for Cancer Gene Therapy (ACGT) is the nations only non-profit dedicated exclusively to cell and gene cancer therapy research. One hundred percent of all contributions to ACGT go directly to research and fund grants with leading scientists in the U.S., representing such institutions as Harvard Medical School, Johns Hopkins University School of Medicine, Mayo Clinic, St. Judes Childrens Hospital, Duke University, The Salk Institute, University of Pennsylvania, Memorial Sloan-Kettering, Stanford University, Dana Farber Cancer Center, University of California San Diego, University of Pittsburgh, and the University of Chicago. A rigorous grant review by Scientific Advisory Council ensures the most promising projects are rewarded. To learn more about the leukemia study at the University of Pennsylvania, and about the Alliance for Cancer Gene Therapy (ACGT), visit http://www.acgtfoundation.org or call 203.358.8000.

See the article here:
Alliance for Cancer Gene Therapy Funds Promising Leukemia Study – Patients in Remission More Than Two Years after Gene ...

Recommendation and review posted by Bethany Smith

1. Introduction and Overview- Biotechnology: Panacea or Pandora #39;s Box NQ
Given the rapid recent advances in genomics, agriculture, transgenic biology, stem cell research and other related areas of biotechnology and a prediction that these fields will continue to mature and become increasingly more sophisticated, there is an growing need to create an informed and educated student in this area. We believe that a working knowledge of DNA, genetics, and biotechnology has become as fundamental to a basic education as an understanding of the solar system. In addition, biotechnology fields offer students career opportunities which is best recognized early in their academics so that they can make the appropriate choices to be best prepared. The rise of recent controversy and misconceptions about many areas of biotechnology including GMOs in food, vaccines and vaccination, personalized medicine, stem cell research and many other topics creates a growing educational challenge. The introduction of a general education course which concentrates on evidence based knowledge on biotechnology and is developed for a general audience with a large potential enrollment is designed to meet that challenge. In turn our experience shows that such a course serves to recruit new scientists and other participants into the careers in the emerging new fields of biotechnology and stimulates further interest in STEM related disciplines. The courses in this series have been established in the curriculum over the past several years with high student demand and interest. Given ...From:Albert KauschViews:0 0ratingsTime:01:05:12More inScience Technology

Read the original here:
1. Introduction and Overview- Biotechnology: Panacea or Pandora's Box NQ - Video

Recommendation and review posted by sam

Regenerative Medicine Center Lebanon
We promise to ensure cell-therapy based applications in a safe and innovative way. We place the highest priority on our commitment to practicing medicine in a way that constantly delivers the safest care possible to every patient.From:revivamedicalViews:0 0ratingsTime:13:59More inPeople Blogs

Read more:
Regenerative Medicine Center Lebanon - Video

Recommendation and review posted by sam

Regenerative Medicine Center, Reviva Lebanon.
Our mission is to bring scientific innovation to patients seeking a trace of hope in new medicine therapy through cellular enhancement and medical excellence. We aim to be recognized as an all-in-one leader center in stem cell and regenerative medicine research and applications in the MENA region.From:revivamedicalViews:0 0ratingsTime:05:59More inPeople Blogs

More here:
Regenerative Medicine Center, Reviva Lebanon. - Video

Recommendation and review posted by sam

Splint- Cell Therapy (Original Mix)
Drumstep. Download for free here: soundcloud.com This is my new channel. Please comment and, above all, share- you have no idea how much it helps. facebook.com/splint.uk soundcloud.com/cyklopsmk7 twitter.com/SamHarris_EBFrom:SplintTVukViews:9 0ratingsTime:05:39More inMusic

Original post:
Splint- Cell Therapy (Original Mix) - Video

Recommendation and review posted by Bethany Smith

Stem Cell Therapy for Animals Q A at Animal Clinic of
- Captured Live on Ustream at http://www.ustream.tvFrom:HawaiiWellnessDirViews:1 0ratingsTime:39:36More inPeople Blogs

Originally posted here:
Stem Cell Therapy for Animals Q

Recommendation and review posted by Bethany Smith

Zell-V Cell Therapy - Best Anti Aging Product
http://www.zell-v.comFrom:zellvsheepplacentaViews:11 0ratingsTime:02:16More inHowto Style

See the original post here:
Zell-V Cell Therapy - Best Anti Aging Product - Video

Recommendation and review posted by Bethany Smith

Alan Fine on Advances in stem cell therapy
Alan Fine, Professor of Medicine, Director Stem Cell Biology Program, Boston University Alan Fine spoke at the Expert Exchange Roundtable on Pushing the boundaries of longevity, 9 September 2011, sSwissnex Boston, Cambridge, Massachusetts, USAFrom:swissretvViews:12 0ratingsTime:01:18:35More inEducation

Follow this link:
Alan Fine on Advances in stem cell therapy - Video

Recommendation and review posted by Bethany Smith

Live Cell Therapy | Stem Cell Malaysia
stemcellmalaysia.com Live cell therapy is one form of stem cell therapy under the hierarchy of cell therapy, which is under regenerative medicine. Live cell therapy was made popular since 1931 by Dr Paul Niehans, who pioneered the therapy using injection. Oral or injection live cell therapy is far more superior than surgical implantation due to several advantages. Today, live cell therapy has been applied to disease treatment, beauty and health rejuvenation. For more information on stem cell therapy, please visit Stem Cell Malaysia at stemcellmalaysia.comFrom:stemcells2012Views:172 10ratingsTime:12:14More inScience Technology

See more here:
Live Cell Therapy | Stem Cell Malaysia - Video

Recommendation and review posted by Bethany Smith

123Triad : fatgraftforumcom
123Triad is proud to design website for http://www.fatgraftforum.com Autologous fat grafting is rapidly becoming the standard in the field of Plastic Surgery and the demand for knowledge and advances in fat grafting have significantly increased. The International Fat Grafting Forum will present renowned physicians from all over the world to promote the advancement of fat grafting technology and techniques including the ongoing debate on stem cell therapy.From:123triadorgViews:2 0ratingsTime:00:36More inScience Technology

Read the rest here:
123Triad : fatgraftforumcom - Video

Recommendation and review posted by Bethany Smith

MissouriCuresEvents_Oct2012_Dr.MarieCsete
"The stem cell therapy race: roadblocks to the finish line", as presented by Dr. Marie Csete at The Danforth Center on behalf of Missouri Cures Education Foundation #39;s Speaker Series in October, 2012.From:MissouriCuresEventsViews:1 0ratingsTime:51:36More inNonprofits Activism

The rest is here:
MissouriCuresEvents_Oct2012_Dr.MarieCsete - Video

Recommendation and review posted by Bethany Smith

Stem Cell Therapy (IMC)
New Project 40From:OmarGonzalezMDViews:0 0ratingsTime:01:48More inScience Technology

Visit link:
Stem Cell Therapy (IMC) - Video

Recommendation and review posted by Bethany Smith

Sources Of Stem Cells | Stem Cell Malaysia
stemcellmalaysia.com Sources of stem cells play a critical role in determining the outcome of stem cell therapy. Without a clear idea of the sources of stem cells, it is risky to be engaged in any form of stem cells treatment. The sources of stem cells include the type of animals, the location of the animals, and the parts of the animal. For more information on sources of stem cells, please visit Stem Cell Malaysia at stemcellmalaysia.comFrom:stemcells2012Views:207 9ratingsTime:04:13More inScience Technology

Read the rest here:
Sources Of Stem Cells | Stem Cell Malaysia - Video

Recommendation and review posted by Bethany Smith

Robert Toves Testimonial (Parkinson #39;s Disease) Stem Cell Therapy
Robert Toves is a patient at Integra Medical Center, Mr.Toves suffers of Parkinson #39;s disease and has come to try Dr.Gonzalez method of stem cell therapy, just less than an hour after the stem cell therapy great results seem to show.From:OmarGonzalezMDViews:0 0ratingsTime:05:58More inScience Technology

Visit link:
Robert Toves Testimonial (Parkinson's Disease) Stem Cell Therapy - Video

Recommendation and review posted by Bethany Smith

Stem Cell Therapy (Cerebral Palsy)
New Project 43From:OmarGonzalezMDViews:0 0ratingsTime:02:07More inScience Technology

More here:
Stem Cell Therapy (Cerebral Palsy) - Video

Recommendation and review posted by Bethany Smith

Emily Whitehead First Child Treated in Trial of T Cell Therapy for Acute Lymphoblastic Leukemia
In April 2012, 7-year-old cancer patient Emily (Emma) Whitehead became the first child to be enrolled in CTL019, a clinical trial for patients with B cell cancers such as acute lymphocytic leukemia (ALL), B cell non-Hodgkin lymphoma (NHL), and the adult disease chronic lymphocytic leukemia (CLL). Emily received this experimental treatment at The Children #39;s Hospital of Philadelphia in April 2012 after her cancer relapsed for the second time. Her cancer has been in remission since her treatment.From:ChildrensHospPhilaViews:6 0ratingsTime:06:45More inScience Technology

More here:
Emily Whitehead First Child Treated in Trial of T Cell Therapy for Acute Lymphoblastic Leukemia - Video

Recommendation and review posted by Bethany Smith

GAITHERSBURG, MD--(Marketwire - Dec 6, 2012) - Cytomedix, Inc. ( OTCQX : CMXI ) (the "Company"), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announced today the signing of an agreement with NIH to collaborate on a Phase 2 clinical study in patients with intermittent claudication (IC).IC is caused by peripheral arterial disease (PAD), a condition causing reduced flow of blood and oxygen to muscles of the leg. The study is being funded by NHLBI/NIH and managed by the Cardiovascular Cell Therapy Research Network (CCTRN), which is also responsible for enrolling patients. The CCTRN is a network that includes seven centers in the United States with experience and expertise in stem cell clinical trials studying treatments for cardiovascular heart diseases.

The Phase 2 PACE (Patients with Intermittent Claudication Injected with ALDH Bright Cells) study is an 80 patient, double-blind, placebo-controlled clinical trial intended to demonstrate the safety and efficacy of ALD-301 (Bright Cells) in patients diagnosed with IC.The primary endpoints of the study are safety and the change in peak walking time at 6 months compared to baseline.Additionally, changes in leg collateral arterial anatomy, calf muscle blood flow, and tissue perfusion as determined by magnetic resonance imaging (MRI) will be examined. These novel MRI techniques are incorporated into the study to assess perfusion, providing a unique set of data potentially supporting the angiogenic mechanism of Bright Cells.The clinical study has received Investigational New Drug approval from the U.S. Food and Drug Administration (FDA) and is expected to begin enrollment in Q1 2013 upon the Investigational Review Board approvals from the participating centers.

Martin P. Rosendale, Chief Executive Officer of Cytomedix, stated, "We are delighted that the CCTRN has chosen to collaborate with Cytomedix on this study.Our February acquisition of Aldagen and the Bright Cell technology has positioned us well to play a leading role in investigating promising clinical paths in regenerative medicine where there exists significant unmet medical need.We look forward to supplying a highly differentiated personalized cell therapy product to the participating CCTRN centers involved with this important PAD indication.Intermittent claudication is a serious consequence of arteriosclerosis which, if left untreated, will likely progress to pain at rest and possibly open wounds.Our experience with the AutoloGel product and the clinical treatment of lower extremity wounds resulting from CLI has provided us with a full appreciation of the difficult clinical outcomes associated with this compromised patient population.We are hopeful that improvements in lower leg blood flow will lead to increased peak walking time which has been accepted as an FDA approvable endpoint in pivotal Phase 3 trials in IC."

"This is the first randomized clinical trial to look at the benefits of autologous stem cell therapy in PAD patients with IC. It will collect important mechanistic and clinical information on the efficacy and safety of the direct injection of Bright Cells into these patients. It will also evaluate the utility of advanced imaging endpoints that could be used in the future to further understand the impact of novel therapies in this patient population," added Lem Moy, M.D., Ph.D., professor of biostatistics at the University of Texas School of Public Health, Houston, and co-author of the study protocol.

PAD is a major unmet medical need affecting approximately 8 to 10 million patients in the U.S. IC is a significant subset of the PAD population and is characterized by pain in the lower legs while in motion that resolves upon rest.Critical limb ischemia (CLI) is the advanced form of PAD, and is associated with poor clinical outcomes and increased morbidity.An important goal of medical intervention is to attempt to prevent the progression of patients from IC to CLI.This clinical studybuilds on the strong data showing increased blood flow and improved clinical status from Cytomedix's previous Phase 1/2 study of ALD-301 in CLI published last year ("A Randomized, Controlled Study of Autologous Therapy with Bone Marrow-Derived Aldehyde Dehydrogenase Bright Cells in Patients with Critical Limb Ischemia" Catheterization and Cardiovascular Interventions 2011).In the PACE study, ALD-301 will be delivered in the same manner, via direct, intramuscular injection in a grid pattern of the affected lower limb.Cytomedix will be responsible for manufacturing ALD-301 for the clinical trial and will have certain rights todata generated during the trial.

About ALD-301/ALDH Bright CellsALD-301 is a population of autologous pluripotent stem cells isolated from the patients' bone marrow using Cytomedix' proprietary Bright Cell technology.These adult stem cells express high levels of the enzyme ALDH, an indicator of biological activity in heterogeneous early stage stem cells.Preclinical research suggests that ALD-301 may promote the repair of ischemic tissue damage by producing signaling molecules that are involved in cell recruitment, cell adhesion, and angiogenesis.

About Cardiovascular Cell Therapy Research Network (CCTRN) and NHLBIThe CCTRN includes seven main stem cell centers in the United States with experience and expertise in clinical trials studying treatments for cardiovascular diseases.They are the Texas Heart Institute, the University of Florida at Gainesville, Minneapolis Heart Institute, Stanford University, University of Louisville, University of Miami and the Vascular and Cardiac Center for Adult Stem Cell Therapy in Indianapolis, Indiana.The CCTRN has successfully completed and published the results of three adult stem cell trials to date (TIME, LateTIME, and FOCUS).Further information on CCTRN is available at: cctrn.org.

The National Heart, Lung, and Blood Institute (NHLBI) is a component of the National Institutes of Health. NHLBI plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders. The Institute also administers national health education campaigns on women and heart disease, healthy weight for children, and other topics. NHLBI press releases and other materials are available at: nhlbi.nih.gov.

About Cytomedix, Inc. Cytomedix, Inc. is an autologous regenerative therapies company commercializing innovative platelet technologies for orthopedics and wound care with a pipeline of adult stem cell therapies for tissue repair. The Company markets the AutoloGel System, a device for the production of autologous platelet rich plasma ("PRP") gel for use on a variety of exuding wounds and the Angel cPRP System, a blood processing device and disposable products used for the separation of blood and bone marrow into red cells, platelet poor plasma ("PPP") and PRP in surgical settings.On February 8, 2012 Cytomedix closed the acquisition of Aldagen, a biopharmaceutical company developing regenerative cell therapies based on its proprietary ALDH bright cell technology, currently in a Phase 2 trial for the treatment of ischemic stroke. For additional information please visit cytomedix.com

Safe Harbor StatementStatements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix' actual results may differ materially due to a number of factors, many of which are beyond Cytomedix' ability to predict or control, including among many others, risks and uncertainties related to the Company's ability to successfully integrate the Aldagen acquisition, to successfully manage contemplated clinical trials, to manage and address the capital needs, human resource, management, compliance and other challenges of a larger, more complex and integrated business enterprise, viability and effectiveness of the Company's sales approach and overall marketing strategies, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, and Cytomedix's ability to execute on its strategy to market the AutoloGel System as contemplated. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as "believes," "forecasted," "projects," "is expected," "remain confident," "will" and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect our future operating results are more fully described in our U.S. Securities and Exchange Commission filings, including our Annual Report for the year ended December 31, 2011 and other subsequent filings. These filings are available at http://www.sec.gov.

Continue reading here:
Cytomedix Announces Landmark Bright Cell Therapy Study in Peripheral Arterial Disease

Recommendation and review posted by Bethany Smith

Trillions for Global GeoEngeneering aka Chemtrails aka Aerosol Crimes
Petition petitions.whitehouse.gov Weather Modification, Inc. bull; 3802 #65279; 20th Street North, Fargo, ND 58102 bull; phone: 1-701-235-5500 bull; fax: #65279; 1-701-235-9717 Weather #65279; Modification, Inc http://www.weathermodification.com Investigating Chemtrails And What Is In Them http://www.stumbleupon.com Queensland went a lot further than that and recommended a very substantial long-term operational trial as well, which would have cost a great deal more than $10-million." http://www.abc.net.au August 1952 RAF in Britain conducted Operation Cumulus, which involved gliders spraying clouds with dry ice, salt or silver iodide. Within days North Devon received 250 times its normal August rainfall. Lynmouth was virtually washed away and 35 people were killed. http://www.theage.com.au June 2010 Australia announced a fast-start package of A$599 million for climate change. And climate change they did.. Inland tsunami #39;s, killing grandparents and kids, record breaking cyclones that made everyone #39;s hearts skip a beat, Ocean life washed ashore, birds dead in the street. http://www.climatechange.gov.au QLD State Government spending $17.6 million annually since 2007 aimed specifically at Geo-engineering CLOUD SEEDING programs. Since mid-January 2008 cloud seeding aircraft have made almost daily passes over the south east coast (Commonly known as CHEMTRAILS). Former Climate Change Minister Andrew McNamara said #39;there would be further flights in the next wet season. This project will focus on the Wivenhoe and Somerset dam catchments. Current ...From:TheKimrobViews:11 3ratingsTime:04:54More inNews Politics

Continue reading here:
Trillions for Global GeoEngeneering aka Chemtrails aka Aerosol Crimes - Video

Recommendation and review posted by Bethany Smith

Zeitgeist Ancient Aliens : Chris White Interview
Chris White, prolific producer of countless painstakingly-researched "debunkumentaries", joins me to discuss his work on #39;Zeitgeist : The Movie #39;, the teachings of David Icke, The History Channel #39;s #39;Ancient Aliens #39; series, and his documentary #39;The New Age Its Relationship to the Antichrist. #39; ...is Jesus a myth? ... are we all the products of extra-terrestrial genetic engineering? Chris White explains. Source: themindrenewed.com Interview Notes: themindrenewed.com Podcast music: Antony Raijekov #39;s #39;Jazz U #39; freemusicarchive.org (CC BY-NC 2.5) creativecommons.orgFrom:TheMindRenewedDotComViews:1 0ratingsTime:01:13:36More inEducation

More:
Zeitgeist

Recommendation and review posted by Bethany Smith

Depths "Genetics of the Subconscious" Timeout
Wheeeeee~From:MalkyrianViews:19 2ratingsTime:01:46More inGaming

More:
Depths "Genetics of the Subconscious" Timeout - Video

Recommendation and review posted by Bethany Smith

Touhou 11 SA - Extra ReimuA 967416080 (no deaths, perfect Koishi battle)
What #39;s interesting is that this wasn #39;t even aiming for a perfect run; it was just a no-death run attempt. Although I took various scoring risks up until Youkai Polygraph, from Rorshach onwards I was ready to bomb. Well, until Subterranean Rose that is. Reaching 10000 graze is just a bonus on top of this. I #39;ve done it before, but only by bombing Koishi (ReimuA can get a decent amount from her spiral nonspells or Rorshach/Genetics). By the way circling around Koishi #39;s 5th nonspell seems easier than her 2nd despite them looking nearly the same. Though I still have yet to survive more than one circle. Why did I focus like that at the end? Not sure. I think it looks weird. Well, at least Reimu the Red Nose is in season. replays.gensokyo.orgFrom:KarisaMirisameViews:30 1ratingsTime:13:49More inGaming

See the article here:
Touhou 11 SA - Extra ReimuA 967416080 (no deaths, perfect Koishi battle) - Video

Recommendation and review posted by Bethany Smith

Nobel Week Dialogue Parallel afternoon discussion panels Stream 2
14:30 - 15:45 2B: Genetics and Nurture: Understanding the Interactions Between Genetics and the Environment Moderator: Matt Ridley Panelists: Bruce Beutler John Dupré Mary-Claire King Helga Nowotny James WatsonFrom:thenobelprizeViews:139 2ratingsTime:02:30:36More inEducation

Go here to read the rest:
Nobel Week Dialogue Parallel afternoon discussion panels Stream 2 - Video

Recommendation and review posted by Bethany Smith

My nephew dancing to Scream and shout!
He cracks me up and is the light of my life. I could give a damn if his genetics are off. He is perfect in my eyes.From:klorissa marchettiViews:0 0ratingsTime:01:31More inPeople Blogs

See more here:
My nephew dancing to Scream and shout! - Video

Recommendation and review posted by Bethany Smith